Clinical trials
Macular Degeneration trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
85 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2006 | 4 |
| 2007 | 6 |
| 2008 | 5 |
| 2009 | 2 |
| 2010 | 5 |
| 2011 | 4 |
| 2012 | 3 |
| 2013 | 5 |
| 2014 | 6 |
| 2015 | 6 |
| 2018 | 3 |
| 2019 | 7 |
| 2020 | 5 |
| 2021 | 3 |
| 2022 | 5 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 5 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 52 |
| Terminated | 11 |
| Recruiting | 9 |
| Unknown status | 6 |
| Active, not recruiting | 5 |
| Suspended | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bayer | 10 |
| Novartis Pharmaceuticals | 9 |
| Allergan | 4 |
| University Hospital, Bonn | 4 |
| Genentech, Inc. | 2 |
| GlaxoSmithKline | 2 |
| Gyroscope Therapeutics Limited | 2 |
| Janssen Research & Development, LLC | 2 |
| Novartis | 2 |
| Ophthotech Corporation | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Macular Degeneration | 85 |
| Geographic Atrophy | 20 |
| Choroidal Neovascularization | 13 |
| Retinal Diseases | 11 |
| Eye Diseases | 10 |
| Vision Disorders | 10 |
| Wet Macular Degeneration | 10 |
| Retinal Degeneration | 9 |
| Macular Edema | 4 |
| Retinal Vein Occlusion | 4 |
Trials
Showing 26 to 50 of 85. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.